RT after Encorafenib and Binimetinib on BRAF mutated melanoma brain metastases. GEM1802-Phase II

被引：0

作者：

Alvarez, A. ^{[1
]}

Valduvieco, I. ^{[2
]}

Arance, A. ^{[3
]}

Delgado, R. ^{[4
]}

Berciano, M. A. ^{[5
]}

Lopez Campos, F. ^{[6
]}

Soria, A. ^{[7
]}

Romero, J. L. ^{[8
]}

Sanchez Maurino, P. ^{[9
]}

Lucas, A. ^{[10
]}

Martin Liberal, J. ^{[10
]}

Prada, P. J. ^{[11
]}

Garcia Castano, A. ^{[12
]}

Alamo, M. C. ^{[13
]}

Puertas, E. ^{[14
]}

Gonzalez Cao, M. ^{[15
]}

Conde, A. ^{[16
]}

Diaz Beveridge, R. ^{[17
]}

Corona, J. A. ^{[18
,19
]}

Aguado, C. ^{[20
]}

Foro, P. ^{[21
]}

Vidal, J. ^{[22
]}

Lopez Soler, F. ^{[23
]}

Cerezuela Fuentes, P. ^{[24
]}

Marquez Rodas, I. ^{[25
]}

机构：

[1] HGU Gregorio Maranon, Madrid, Spain

[2] H Clin, Radiat Oncol, Barcelona, Spain

[3] H Clin, Med Oncol, Barcelona, Spain

[4] H Reg Malaga, Radiat Oncol, Malaga, Spain

[5] HU Reg & Virgen de la Victoria, Med Oncol, Unidad Gest Intercentros, Malaga, Spain

[6] H Ramon y Cajal, Radiat Oncol, Madrid, Spain

[7] H Ramon y Cajal, Med Oncol, Madrid, Spain

[8] HU Reina Sofia, Radiat Oncol, Cordoba, Spain

[9] HU Reina Sofia, Med Oncol, Cordoba, Spain

[10] ICO LHospitalet, Radiat Oncol, Barcelona, Spain

[11] ICO LHospitalet, Med Oncol, Barcelona, Spain

[12] H Valdecilla, Radiat Oncol, Santander, Spain

[13] H Valdecilla, Med Oncol, Santander, Spain

[14] HU Virgen Macarena, Med Oncol, Seville, Spain

[15] HU Dexeus, Radiat Oncol, Barcelona, Spain

[16] HU Dexeus, Med Oncol, Barcelona, Spain

[17] H la Fe, Radiat Oncol, Valencia, Spain

[18] H la Fe, Med Oncol, Valencia, Spain

[19] H Clin San Carlos, Radiat Oncol, Madrid, Spain

[20] H Clin San Carlos, Med Oncol, Madrid, Spain

[21] H del Mar, Radiat Oncol, Barcelona, Spain

[22] H del Mar, Med Oncol, Barcelona, Spain

[23] HCU Virgen de la Arrixaca, IMIB, Radiat Oncol, Murcia, Spain

[24] HCU Virgen de la Arrixaca, IMIB, Med Oncol, Murcia, Spain

[25] HGU Gregorio Maranon, Madrid, Spain

来源：

RADIOTHERAPY AND ONCOLOGY | 2023年 / 182卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PO-1557

引用

下载

页码：S1264 / S1264

页数：1

共 30 条

[1] Encorafenib and binimetinib followed by radiotherapy for patients with symptomatic BRAF mutated melanoma brain metastases: GEM1802/E-BRAIN clinical trial
Marquez-Rodas, I.
Arance Fernandez, A. M.
Berciano Guerrero, M. A.
Garcia Castano, A.
Alamo De La Gala, M. D. C.
Gonzalez Cao, M.
Sanchez Maurino, P.
Diaz Beveridge, R. P.
Valduvieco, I.
Delgado, R.
Prada, P. J.
Puertas, E.
Romero, J. L.
Conde, A.
Alvarez, A.
Berrocal, A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S926 - S926
[2] Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial
Marquez-Rodas, I.
Arance, A.
Berciano Guerrero, M. A.
Diaz Beveridge, R.
Alamo, M. D. C.
Garcia Castano, A.
Gonzalez Cao, M.
Vidal, J.
Puertolas Hernandez, T.
Soria, A.
Aguado De la Rosa, C.
Sanchez Maurino, P.
Valduvieco, I.
Delgado Rico, R.
Conde, A.
Foro, P.
Prada, P. J.
Puertas, E.
Alvarez Gonzalez, A.
Berrocal, A.
ANNALS OF ONCOLOGY, 2021, 32 : S870 - S870
[3] Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study)
Marquez-Rodas, Ivan
Alvarez, Ana
Arance, Ana
Valduvieco, Izaskun
Berciano-Guerrero, Miguel-angel
Delgado, Raquel
Soria, Ainara
Campos, Fernando Lopez
Sanchez, Pedro
Romero, Jose Luis
Martin-Liberal, Juan
Lucas, Anna
Diaz-Beveridge, Roberto
Conde-Moreno, Antonio-Jose
de la Gala, Maria del Carmen Alamo
Garcia-Castano, Almudena
Prada, Pedro Jose
Cao, Maria Gonzalez
Puertas, Enrique
Vidal, Joana
Foro, Palmira
de la Rosa, Carlos Aguado
Corona, Juan Antonio
Cerezuela-Fuentes, Pablo
Lopez, Paco
Luna, Pablo
Aymar, Neus
Puertolas, Teresa
Sanagustin, Pilar
Berrocal, Alfonso
NEURO-ONCOLOGY, 2024,
[4] Complete response of brainstem metastasis in BRAF-mutated melanoma without stereotactic radiosurgery after initiation of encorafenib and binimetinib
Khullar, Karishma
Hanft, Simon
Mehnert, Janice M.
Weiner, Joseph P.
MELANOMA RESEARCH, 2021, 31 (04) : 393 - 396
[5] Clinical and Radiographic Response of Leptomeningeal and Brain Metastases to Encorafenib and Binimetinib in a Patient With BRAF V600E-Mutated Lung Adenocarcinoma
McLoughlin, Erin M.
Fadul, Camilo E.
Patel, Sohil H.
Hall, Richard D.
Gentzler, Ryan D.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (12) : E269 - E271
[6] A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2).
Dummer, Reinhard
Sandhu, Shahneen Kaur
Miller, Wilson H.
Butler, Marcus O.
Blank, Christian U.
Munoz-Couselo, Eva
Burris, Howard A., III
Postow, Michael A.
Chmielowski, Bartosz
Middleton, Mark R.
Berking, Carola
Hassel, Jessica Cecile
Gesierich, Anja
Mauch, Cornelia
Kleha, Joseph
Gollerkeri, Ashwin
Harney, Allison
Pickard, Michael D.
Ascierto, Paolo Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[7] COLUMBUS-AD: phase III study of adjuvant encorafenib plus binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma
van Akkooi, Alexander C. J.
Hauschild, Axel
Long, Georgina, V
Mandala, Mario
Kicinski, Michal
Govaerts, Anne-Sophie
Klauck, Isabelle
Ouali, Monia
Lorigan, Paul C.
Eggermont, Alexander M. M.
FUTURE ONCOLOGY, 2023, 19 (30) : 2017 - 2027
[8] Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
Ascierto, Paolo A. A.
Mandala, Mario
Ferrucci, Pier Francesso
Guidoboni, Massimo
Rutkowski, Piotr
Ferraresi, Virginia
Arance, Ana
Guida, Michele
Maiello, Evaristo
Gogas, Helen
Richtig, Erika
Fierro, Maria Teresa
Lebbe, Celeste
Helgadottir, Hildur
Queirolo, Paola
Spagnolo, Francesco
Tucci, Marco
Del Vecchio, Michele
Gonzales Cao, Maria
Minisini, Alessandro Marco
De Placido, Sabino
Sanmamed, Miguel F. F.
Mallardo, Domenico
Curvietto, Marcello
Melero, Ignacio
Palmieri, Giuseppe
Grimaldi, Antonio M.
Giannarelli, Diana
Dummer, Reinhard
Sileni, Vanna Chiarion
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) : 212 - +
[9] SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study
Ascierto, P. A.
Mandala, M.
Ferrucci, P. F.
Rutkowski, P.
Guidoboni, M.
Fernandez, A. M. Arance
Ferraresi, V.
Maiello, E.
Guida, M.
Del Vecchio, M.
Fierro, M. T.
Queirolo, P.
Lebbe, C.
Helgadottir, H.
Melero, I.
Palmieri, G.
Giannarelli, D.
Grimaldi, A. M.
Dummer, R.
Sileni, V. Chiarion
ANNALS OF ONCOLOGY, 2021, 32 : S1316 - S1317
[10] Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma.
Jameson-Lee, Max
Ott, Patrick Alexander
Luke, Jason J.
Postow, Michael A.
Poklepovic, Andrew Stewart
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 →